FIELD: chemistry.
SUBSTANCE: claimed invention relates to field of biotechnology, in particular to novel peptide analogue of insulin-like growth factor-1 (IGF-1), which contains amino acid substitution of methionine in position 59 on Asn, Leu, Nle, Ile, Arg, A6c, Glu, Trp or Tyr, as well as other additional substitutions, inserts and deletions. Said peptide or its pharmaceutically acceptable salt is used in composition of pharmaceutical composition for treatment of IGF-1-mediated diseases, as well as in method of treating dwarfism.
EFFECT: invention makes it possible to obtain IGF-1 analogue-agonist, possessing higher biological activity with respect to native IGF-1.
17 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| HUMANIZED ANTIBODY AGAINST IGF-1 RECEPTOR | 2019 |
|
RU2784079C1 |
| MIC-1 COMPOUNDS AND THEIR USE | 2017 |
|
RU2776529C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS FOR USING THEM | 2017 |
|
RU2739504C2 |
| METHOD OF GLP-1 MOLECULES INTRODUCTION | 2003 |
|
RU2332229C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| TREATMENT OF NEUROPATHY WITH DNA STRUCTURES ENCODING IGF-1 AND DNA STRUCTURES ENCODING HGF | 2019 |
|
RU2781980C2 |
